C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 812—Investigational Device ExemptionsSubpart B—Application and Administrative Action

21 C.F.R. § 812.25 (2026)

Investigational plan

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1993–2021 9citing cases
At a glance

Courts have cited this section in 9 opinions since 1993, 2 of them in the last five years.

The investigational plan shall include, in the following order:

(a) Purpose. The name and intended use of the device and the objectives and duration of the investigation.

(b) Protocol. A written protocol describing the methodology to be used and an analysis of the protocol demonstrating that the investigation is scientifically sound.

(c) Risk analysis. A description and analysis of all increased risks to which subjects will be exposed by the investigation; the manner in which these risks will be minimized; a justification for the investigation; and a description of the patient population, including the number, age, sex, and condition.

(d) Description of device. A description of each important component, ingredient, property, and principle of operation of the device and of each anticipated change in the device during the course of the investigation.

(e) Monitoring procedures. The sponsor's written procedures for monitoring the investigation and the name and address of any monitor.

(f) Labeling. Copies of all labeling for the device.

(g) Consent materials. Copies of all forms and informational materials to be provided to subjects to obtain informed consent.

(h) IRB information. A list of the names, locations, and chairpersons of all IRB's that have been or will be asked to review the investigation, and a certification of any action taken by any of those IRB's with respect to the investigation.

(i) Other institutions. The name and address of each institution at which a part of the investigation may be conducted that has not been identified in paragraph (h) of this section.

(j) Additional records and reports. A description of records and reports that will be maintained on the investigation in addition to those prescribed in subpart G.

The 9 cases that cite 21 C.F.R. § 812.25 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENAda M. Martin v. Telectronics Pacing Sys., Inc., 105 F.3d 1090 (6th Cir. 1997).
cites § 812.25 3×cited by 52 cases
Where it cites § 812.25
“Pursuant to 21 C.F.R. § 812.25 , the manufacturer must submit a detailed statement regarding the intended use of the device and the objectives and planned duration of the investigational study; a written protocol describing the methodology to be used and an *1096 analysis of the…”
The case’s holding
State products liability claims are preempted when specific federal regulations apply to the device in question, such as those governing an investigational device exemption.
Later courts cite it for
“federal requirement 'must be applicable to the device in question... and specific to a particular device.” · 3 citing courts
2
GREENGuckin v. Nagle, 259 F. Supp. 2d 406 (E.D. Pa. 2003).
cites § 812.25 1×cited by 8 cases
Where it cites § 812.25
“5 , and whether the consent materials comply with the provisions of 21 C.F.R. § 812.25 (g) and 21 C.F.R. § 50.”
3
GREENChmielewski v. Stryker Sales Corp., 966 F. Supp. 839 (D. Minn. 1997).
cites § 812.25 1×cited by 12 cases
Where it cites § 812.25
“21 C.F.R. § 812.25 . The MDA contains an express preemption provision: Except as provided in subsection (b) of this section, no State or political subdivision of a State may establish or continue in effect with respect to a device intended for human use any requirement— (1)…”
Later courts cite it for
“the fact that plaintiffs' claims are based on general common law duties does not save them from being preempted,, if a conflicting device-specific federal regulation exists.” · 1 citing court
4
GREENKonrady v. Oesterling, 149 F.R.D. 592 (D. Minn. 1993).
cites § 812.25 1×cited by 4 cases
Where it cites § 812.25
“Importantly, the Investigational Plan also describes evaluation criteria and documentation procedures which will enable the manufacturer and the FDA to evaluate the device as the investigation proceeds.”
5
GREENNexell Therapeutics, Inc. v. Amcell Corp., 143 F. Supp. 2d 407 (D. Del. 2001).
cites § 812.25 1×cited by 2 cases
Where it cites § 812.25
“See also 21 C.F.R. § 812.25 . After the FDA reviews the plan and grants an IDE, the manufacturer may begin the clinical trials.”
6
GREENIsbell v. Medtronic, Inc., 97 F. Supp. 2d 849 (W.D. Tenn. 1998).
cites § 812.25 1×cited by 1 case
Where it cites § 812.25
“Pursuant to 21 C.F.R. § 812.25 , the manufacturer must submit a detailed statement regarding the intended use of the device and the objectives and planned duration of the investigational study; a written protocol describing the methodology to be used and an analysis of the…”
7
NEUTRALChambers v. Osteonics Corp., 917 F. Supp. 624 (S.D. Ind. 1996).
cites § 812.25 1×cited by 1 case
Where it cites § 812.25
“Although regulations prohibit the inclusion of exculpatory language by which a subject waives or appears to waive any legal rights, the consent form is required to at least alert the subject to the possibility of the loss of certain legal rights. See 21 C.”
8
GREENTeal v. Argon Med. Devices, Inc., 533 F. Supp. 3d 535 (E.D. Mich. 2021).
cites § 812.25 1×cited by 0 casesunknown
Where it cites § 812.25
“Judicial Notice As a preliminary matter, Rex requests that the Court take judicial notice of several FDA documents: (1) FDA website publication on Pre-market Notification/510(k) Clearance Process; (2) Guidance for Cardiovascular Intravascular Filter 510(k) Submissions; and (3)…”
Later courts cite it for
“(1) proof of an express warranty, (2) reliance by the plaintiff; 12 (3) the failure of the product to meet the warranty, and (4) damages caused by the 13 failure.” · 2 citing courts
9
GREENSuttman-Villars v. Argon Med. Devices, Inc, 553 F. Supp. 3d 946 (D.N.M. 2021).
cites § 812.25 1×cited by 0 casesunknown
Where it cites § 812.25
“II Discussion As an initial matter, Rex requests that the Court take judicial notice of three FDA documents: (1) an “FDA website publication on Pre-market Notification/5 10(k) clearance process;” (2) the FDA’s “Guidance for Cardiovascular Intravascular Filter 510(k)…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320072021

One bar per year. Tallest: 2 cases in 1997. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D. Minn.26th Cir.1D. Del.1S.D. Ind.1E.D. Mich.1D.N.M.1E.D. Pa.1W.D. Tenn.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com